How does SHIP1/2 balance PtdIns(3,4)P2 and does it signal independently of its phosphatase activity?

BioEssays

Volumn 35, Issue 8, 2013, Pages 733-743

  Xie, Jingwei ^a   Erneux, Christophe ^b   Pirson, Isabelle ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

EGFR endocytosis; Mono ubiquitination; PtdIns(3,4)P2; Scaffold properties; SHIP1 2

Indexed keywords

GROWTH FACTOR RECEPTOR; INSULIN; PHOSPHATASE; PHOSPHATIDYLINOSITIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4 BISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PROTEIN TYROSINE PHOSPHATASE SHP; SCAFFOLD PROTEIN;

ARTICLE; B LYMPHOCYTE ACTIVATION; CELL ADHESION; CELL MEMBRANE; CELL MIGRATION; DENT DISEASE; ENDOCYTOSIS; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FEEDBACK SYSTEM; HEMATOPOIETIC SYSTEM; INSULIN SENSITIVITY; LOWE SYNDROME; NONHUMAN; PHENOTYPE; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; UBIQUITINATION;

EGFR ENDOCYTOSIS; MONO-UBIQUITINATION; PTDINS(3,4)P2; SCAFFOLD PROPERTIES; SHIP1/2;

ANIMALS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL NUCLEUS; CYTOSKELETON; ENDOCYTOSIS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INSULIN; PHOSPHATIDYLINOSITOL PHOSPHATES; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 84880331152     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201200168     Document Type: Article

References (116)

1. McCrea HJ, De Camilli P. 2009. Mutations in phosphoinositide metabolizing enzymes and human disease. Physiology (Bethesda) 24: 8-16.
2. Vanhaesebroeck B, Stephens L, Hawkins P. 2012. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol 13: 195-203.
3. Guo S, Stolz LE, Lemrow SM, York JD. 1999. SAC1-like domains of yeast SAC1, INP52, and INP53 and of human synaptojanin encode polyphosphoinositide phosphatases. J Biol Chem 274: 12990-5.
4. Sbrissa D, Ikonomov OC, Fu Z, Ijuin T, et al. 2007. Core protein machinery for mammalian phosphatidylinositol 3, 5-bisphosphate synthesis and turnover that regulates the progression of endosomal transport. Novel Sac phosphatase joins the ArPIKfyve-PIKfyve complex. J Biol Chem 282: 23878-91.
5. Di Paolo G, De Camilli P. 2006. Phosphoinositides in cell regulation and membrane dynamics. Nature 443: 651-7.
6. Norris FA, Majerus PW. 1994. Hydrolysis of phosphatidylinositol 3, 4-bisphosphate by inositol polyphosphate 4-phosphatase isolated by affinity elution chromatography. J Biol Chem 269: 8716-20.
7. Ivetac I, Munday AD, Kisseleva MV, Zhang XM, et al. 2005. The type Ialpha inositol polyphosphate 4-phosphatase generates and terminates phosphoinositide 3-kinase signals on endosomes and the plasma membrane. Mol Biol Cell 16: 2218-33.
8. Sharma M, Batra J, Mabalirajan U, Sharma S, et al. 2008. A genetic variation in inositol polyphosphate 4 phosphatase a enhances susceptibility to asthma. Am J Respir Crit Care Med 177: 712-9.
9. LaTulippe E, Satagopan J, Smith A, Scher H, et al. 2002. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 62: 4499-506.
10. Erkeland SJ, Valkhof M, Heijmans-Antonissen C, van Hoven-Beijen A, et al. 2004. Large-scale identification of disease genes involved in acute myeloid leukemia. J Virol 78: 1971-80.
11. Gewinner C, Wang ZC, Richardson A, Teruya-Feldstein J, et al. 2009. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 16: 115-25.
12. Agoulnik IU, Hodgson MC, Bowden WA, Ittmann MM. 2011. INPP4B: the new kid on the PI3K block. Oncotarget 2: 321-8.
13. Barnache S, Le Scolan E, Kosmider O, Denis N, et al. 2006. Phosphatidylinositol 4-phosphatase type II is an erythropoietin-responsive gene. Oncogene 25: 1420-3.
14. Fedele CG, Ooms LM, Ho M, Vieusseux J, et al. 2010. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci USA 107: 22231-6.
15. Hodgson MC, Shao LJ, Frolov A, Li R, et al. 2011. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res 71: 572-82.
16. Sasaki T, Takasuga S, Sasaki J, Kofuji S, et al. 2009. Mammalian phosphoinositide kinases and phosphatases. Prog Lipid Res 48: 307-43.
17. Stephens LR, Jackson TR, Hawkins PT. 1993. Agonist-stimulated synthesis of phosphatidylinositol(3, 4, 5)-trisphosphate: a new intracellular signalling system? Biochim Biophys Acta 1179: 27-75.
18. Manning BD, Cantley LC. 2007. AKT/PKB signaling: navigating downstream. Cell 129: 1261-74.
19. Dyson JM, Fedele CG, Davies EM, Becanovic J, et al. 2012. Phosphoinositide phosphatases: just as important as the kinases. Subcell Biochem 58: 215-79.
20. Suwa A, Kurama T, Shimokawa T. 2010. SHIP2 and its involvement in various diseases. Expert Opin Ther Targets 14: 727-37.
21. Attree O, Olivos IM, Okabe I, Bailey LC, et al. 1992. The Lowe's oculocerebrorenal syndrome gene encodes a protein highly homologous to inositol polyphosphate-5-phosphatase. Nature 358: 239-42.
22. Hoopes RR, Jr, Shrimpton AE, Knohl SJ, Hueber P, et al. 2005. Dent disease with mutations in OCRL1. Am J Hum Genet 76: 260-7.
23. Pirruccello M, De Camilli P. 2012. Inositol 5-phosphatases: insights from the Lowe syndrome protein OCRL. Trends Biochem Sci 37: 134-43.
24. Jacoby M, Cox JJ, Gayral S, Hampshire DJ, et al. 2009. INPP5E mutations cause primary cilium signaling defects, ciliary instability and ciliopathies in human and mouse. Nat Genet 41: 1027-31.
25. Bielas SL, Silhavy JL, Brancati F, Kisseleva MV, et al. 2009. Mutations in INPP5E, encoding inositol polyphosphate-5-phosphatase E, link phosphatidyl inositol signaling to the ciliopathies. Nat Genet 41: 1032-6.
26. Pesesse X, Deleu S, De Smedt F, Drayer L, et al. 1997. Identification of a second SH2-domain-containing protein closely related to the phosphatidylinositol polyphosphate 5-phosphatase SHIP. Biochem Biophys Res Commun 239: 697-700.
27. Blero D, Zhang J, Pesesse X, Payrastre B, et al. 2005. Phosphatidylinositol 3, 4, 5-trisphosphate modulation in SHIP2-deficient mouse embryonic fibroblasts. FEBS J 272: 2512-22.
28. Elong Edimo WE, Janssens V, Waelkens E, Erneux C. 2012. Reversible Ser/Thr SHIP phosphorylation: a new paradigm in phosphoinositide signalling? BioEssays 34: 634-42.
29. Deneubourg L, Vanderwinden JM, Erneux C. 2010. Regulation of SHIP2 function through plasma membrane interaction. Adv Enzyme Regul 50: 262-71.
30. Erneux C, Elong Edimo WE, Deneubourg L, Pirson I. 2011. SHIP2 multiple functions: a balance between a negative control of PtdIns(3, 4, 5)P(3) level, a positive control of PtdIns(3, 4)P(2) production and intrinsic docking properties. J Cell Biochem 112: 2203-9.
31. Pesesse X, Dewaste V, De Smedt F, Laffargue M, et al. 2001. The Src homology 2 domain containing inositol 5-phosphatase SHIP2 is recruited to the epidermal growth factor (EGF) receptor and dephosphorylates phosphatidylinositol 3, 4, 5-trisphosphate in EGF-stimulated COS-7 cells. J Biol Chem 276: 28348-55.
32. Wang Y, Keogh RJ, Hunter MG, Mitchell CA, et al. 2004. SHIP2 is recruited to the cell membrane upon macrophage colony-stimulating factor (M-CSF) stimulation and regulates M-CSF-induced signaling. J Immunol 173: 6820-30.
33. Batty IH, van der KJ, Gray A, Telfer JF, et al. 2007. The control of phosphatidylinositol 3, 4-bisphosphate concentrations by activation of the Src homology 2 domain containing inositol polyphosphate 5-phosphatase 2, SHIP2. Biochem J 407: 255-66.
34. Olsen JV, Blagoev B, Gnad F, Macek B, et al. 2006. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127: 635-48.
35. Wisniewski D, Strife A, Swendeman S, Erdjument-Bromage H, et al. 1999. A novel SH2-containing phosphatidylinositol 3, 4, 5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells. Blood 93: 2707-20.
36. Prasad N, Topping RS, Decker SJ. 2002. Src family tyrosine kinases regulate adhesion-dependent tyrosine phosphorylation of 5′-inositol phosphatase SHIP2 during cell attachment and spreading on collagen I. J Cell Sci 115: 3807-15.
37. Brehme M, Hantschel O, Colinge J, Kaupe I, et al. 2009. Charting the molecular network of the drug target Bcr-Abl. Proc Natl Acad Sci USA 106: 7414-9.
38. Balla T. 2005. Inositol-lipid binding motifs: signal integrators through protein-lipid and protein-protein interactions. J Cell Sci 118: 2093-104.
39. Thomas CC, Deak M, Alessi DR, van Aalten DM. 2002. High-resolution structure of the pleckstrin homology domain of protein kinase b/akt bound to phosphatidylinositol (3, 4, 5)-trisphosphate. Curr Biol 12: 1256-62.
40. Ferguson KM, Kavran JM, Sankaran VG, Fournier E, et al. 2000. Structural basis for discrimination of 3-phosphoinositides by pleckstrin homology domains. Mol Cell 6: 373-84.
41. Leslie NR, Dixon MJ, Schenning M, Gray A, et al. 2011. Distinct inactivation of PI3K signalling by PTEN and 5-phosphatases. Adv Enzyme Regul 52: 205-13.
42. Dixon MJ, Gray A, Boisvert FM, Agacan M, et al. 2011. A screen for novel phosphoinositide 3-kinase effector proteins. Mol Cell Proteomics 10: M110.003178.
43. De Schutter J, Guillabert A, Imbault V, Degraef C, et al. 2009. SHIP2 (SH2 domain-containing inositol phosphatase 2) SH2 domain negatively controls SHIP2 monoubiquitination in response to epidermal growth factor. J Biol Chem 284: 36062-76.
44. Ruschmann J, Ho V, Antignano F, Kuroda E, et al. 2010. Tyrosine phosphorylation of SHIP promotes its proteasomal degradation. Exp Hematol 38: 392-402.
45. Sattler M, Verma S, Pride YB, Salgia R, et al. 2001. SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL. J Biol Chem 276: 2451-8.
46. Stampoulis P, Ueda T, Matsumoto M, Terasawa H, et al. 2012. Atypical membrane-embedded phosphatidylinositol 3, 4-bisphosphate (PI(3, 4)P2)-binding site on p47(phox) Phox homology (PX) domain revealed by NMR. J Biol Chem 287: 17848-59.
47. Dowler S, Currie RA, Campbell DG, Deak M, et al. 2000. Identification of pleckstrin-homology-domain-containing proteins with novel phosphoinositide-binding specificities. Biochem J 351: 19-31.
48. Manna D, Albanese A, Park WS, Cho W. 2007. Mechanistic basis of differential cellular responses of phosphatidylinositol 3, 4-bisphosphate- and phosphatidylinositol 3, 4, 5-trisphosphate-binding pleckstrin homology domains. J Biol Chem 282: 32093-105.
49. Kimber WA, Trinkle-Mulcahy L, Cheung PC, Deak M, et al. 2002. Evidence that the tandem-pleckstrin-homology-domain-containing protein TAPP1 interacts with Ptd(3, 4)P2 and the multi-PDZ-domain-containing protein MUPP1 in vivo. Biochem J 361: 525-36.
50. Wullschleger S, Wasserman DH, Gray A, Sakamoto K, et al. 2011. Role of TAPP1 and TAPP2 adaptor binding to PtdIns(3, 4)P2 in regulating insulin sensitivity defined by knock-in analysis. Biochem J 434: 265-74.
51. Landego I, Jayachandran N, Wullschleger S, Zhang TT, et al. 2012. Interaction of TAPP adapter proteins with phosphatidylinositol (3, 4)-bisphosphate regulates B-cell activation and autoantibody production. Eur J Immunol 42: 2760-70.
52. Scheid MP, Huber M, Damen JE, Hughes M, et al. 2002. Phosphatidylinositol (3, 4, 5)P3 is essential but not sufficient for protein kinase B (PKB) activation; phosphatidylinositol (3, 4)P2 is required for PKB phosphorylation at Ser-473: studies using cells from SH2-containing inositol-5-phosphatase knockout mice. J Biol Chem 277: 9027-35.
53. Sleeman MW, Wortley KE, Lai KM, Gowen LC, et al. 2005. Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesity. Nat Med 11: 199-205.
54. Dubois E, Jacoby M, Blockmans M, Pernot E, et al. 2012. Developmental defects and rescue from glucose intolerance of a catalytically-inactive novel Ship2 mutant mouse. Cell Signal 24: 1971-80.
55. Onnockx S, De SJ, Blockmans M, Xie J, et al. 2008. The association between the SH2-containing inositol polyphosphate 5-phosphatase 2 (SHIP2) and the adaptor protein APS has an impact on biochemical properties of both partners. J Cell Physiol 214: 260-72.
56. Marshall AJ, Krahn AK, Ma K, Duronio V, et al. 2002. TAPP1 and TAPP2 are targets of phosphatidylinositol 3-kinase signaling in B cells: sustained plasma membrane recruitment triggered by the B-cell antigen receptor. Mol Cell Biol 22: 5479-91.
57. Muraille E, Pesesse X, Kuntz C, Erneux C. 1999. Distribution of the src-homology-2-domain-containing inositol 5-phosphatase SHIP-2 in both non-haemopoietic and haemopoietic cells and possible involvement of SHIP-2 in negative signalling of B-cells. Biochem J 342: 697-705.
58. Gratacap MP, Severin S, Chicanne G, Plantavid M, et al. 2008. Different roles of SHIP1 according to the cell context: the example of blood platelets. Adv Enzyme Regul 48: 240-52.
59. Pauls SD, Lafarge ST, Landego I, Zhang T, et al. 2012. The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions. Front Immunol 3: 224.
60. Helgason CD, Antonchuk J, Bodner C, Humphries RK. 2003. Homeostasis and regeneration of the hematopoietic stem cell pool are altered in SHIP-deficient mice. Blood 102: 3541-7.
61. Hamilton MJ, Ho VW, Kuroda E, Ruschmann J, et al. 2011. Role of SHIP in cancer. Exp Hematol 39: 2-13.
62. Brauer H, Strauss J, Wegner W, Muller-Tidow C, et al. 2012. Leukemia-associated mutations in SHIP1 inhibit its enzymatic activity, interaction with the GM-CSF receptor and Grb2, and its ability to inactivate PI3K/AKT signaling. Cell Signal 24: 2095-101.
63. Severin S, Gratacap MP, Lenain N, Alvarez L, et al. 2007. Deficiency of Src homology 2 domain-containing inositol 5-phosphatase 1 affects platelet responses and thrombus growth. J Clin Invest 117: 944-52.
64. Elong Edimo W, Vanderwinden JM, Erneux C. 2012. SHIP2 signalling at the plasma membrane, in the nucleus and at focal contacts. Adv Biol Regul 53: 28-37.
65. Prasad NK, Decker SJ. 2005. SH2-containing 5′-inositol phosphatase, SHIP2, regulates cytoskeleton organization and ligand-dependent down-regulation of the epidermal growth factor receptor. J Biol Chem 280: 13129-36.
66. Prasad NK. 2009. SHIP2 phosphoinositol phosphatase positively regulates EGFR-Akt pathway, CXCR4 expression, and cell migration in MDA-MB-231 breast cancer cells. Int J Oncol 34: 97-105.
67. Prasad N, Topping RS, Decker SJ. 2001. SH2-containing inositol 5′-phosphatase SHIP2 associates with the p130(Cas) adapter protein and regulates cellular adhesion and spreading. Mol Cell Biol 21: 1416-28.
68. Dyson JM, O'Malley CJ, Becanovic J, Munday AD, et al. 2001. The SH2-containing inositol polyphosphate 5-phosphatase, SHIP-2, binds filamin and regulates submembraneous actin. J Cell Biol 155: 1065-80.
69. Dyson JM, Munday AD, Kong AM, Huysmans RD, et al. 2003. SHIP-2 forms a tetrameric complex with filamin, actin, and GPIb-IX-V: localization of SHIP-2 to the activated platelet actin cytoskeleton. Blood 102: 940-8.
70. Vandenbroere I, Paternotte N, Dumont JE, Erneux C, et al. 2003. The c-Cbl-associated protein and c-Cbl are two new partners of the SH2-containing inositol polyphosphate 5-phosphatase SHIP2. Biochem Biophys Res Commun 300: 494-500.
71. Paternotte N, Zhang J, Vandenbroere I, Backers K, et al. 2005. SHIP2 interaction with the cytoskeletal protein vinexin. FEBS J 272: 6052-66.
72. Oikawa T, Takenawa T. 2009. PtdIns(3, 4)P2 instigates focal adhesions to generate podosomes. Cell Adhes Migr 3: 195-7.
73. Venkatareddy M, Cook L, Abuarquob K, Verma R, et al. 2011. Nephrin regulates lamellipodia formation by assembling a protein complex that includes Ship2, filamin and lamellipodin. PLoS ONE 6: e28710.
74. Krause M, Leslie JD, Stewart M, Lafuente EM, et al. 2004. Lamellipodin, an Ena/VASP ligand, is implicated in the regulation of lamellipodial dynamics. Dev Cell 7: 571-83.
75. Yoshinaga S, Ohkubo T, Sasaki S, Nuriya M, et al. 2012. A phosphatidylinositol lipids system, lamellipodin, and Ena/VASP regulate dynamic morphology of multipolar migrating cells in the developing cerebral cortex. J Neurosci 32: 11643-56.
76. Kato K, Yazawa T, Taki K, Mori K, et al. 2012. The inositol 5-phosphatase SHIP2 is an effector of RhoA and is involved in cell polarity and migration. Mol Biol Cell 23: 2593-604.
77. Smith K, Humphreys D, Hume PJ, Koronakis V. 2010. Enteropathogenic Escherichia coli recruits the cellular inositol phosphatase SHIP2 to regulate actin-pedestal formation. Cell Host Microbe 7: 13-24.
78. Rameh LE, Tolias KF, Duckworth BC, Cantley LC. 1997. A new pathway for synthesis of phosphatidylinositol-4, 5-bisphosphate. Nature 390: 192-6.
79. Pesesse X, Moreau C, Drayer AL, Woscholski R, et al. 1998. The SH2 domain containing inositol 5-phosphatase SHIP2 displays phosphatidylinositol 3, 4, 5-trisphosphate and inositol 1, 3, 4, 5-tetrakisphosphate 5-phosphatase activity. FEBS Lett 437: 301-3.
80. Taylor V, Wong M, Brandts C, Reilly L, et al. 2000. 5′ Phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells. Mol Cell Biol 20: 6860-71.
81. Elong Edimo W, Derua R, Janssens V, Nakamura T, et al. 2011. Evidence of SHIP2 Ser132 phosphorylation, its nuclear localization and stability. Biochem J 439: 391-401.
82. Nakatsu F, Perera RM, Lucast L, Zoncu R, et al. 2010. The inositol 5-phosphatase SHIP2 regulates endocytic clathrin-coated pit dynamics. J Cell Biol 190: 307-15.
83. Rajala RV, Anderson RE. 2010. Focus on molecules: phosphatidylinositol-4, 5-bisphosphate (PIP2). Exp Eye Res 91: 324-5.
84. O'Bryan JP. 2010. Intersecting pathways in cell biology. Sci Signal 3: re10.
85. Wong KA, Wilson J, Russo A, Wang L, et al. 2012. Intersectin (ITSN) family of scaffolds function as molecular hubs in protein interaction networks. PLoS ONE 7: e36023.
86. Okur MN, Ooi J, Fong CW, Martinez N, et al. 2012. Intersectin 1 enhances Cbl ubiquitylation of epidermal growth factor receptor through regulation of Sprouty2-Cbl interaction. Mol Cell Biol 32: 817-25.
87. Xie J, Vandenbroere I, Pirson I. 2008. SHIP2 associates with intersectin and recruits it to the plasma membrane in response to EGF. FEBS Lett 582: 3011-7.
88. Sorkin A, Goh LK. 2009. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 315: 683-96.
89. Bao M, Hanabuchi S, Facchinetti V, Du Q, et al. 2012. CD2AP/SHIP1 complex positively regulates plasmacytoid dendritic cell receptor signaling by inhibiting the E3 ubiquitin ligase Cbl. J Immunol 189: 786-92.
90. Trotman LC, Wang X, Alimonti A, Chen Z, et al. 2007. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 128: 141-56.
91. Wang X, Trotman LC, Koppie T, Alimonti A, et al. 2007. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128: 129-39.
92. Leone M, Cellitti J, Pellecchia M. 2008. NMR studies of a heterotypic Sam-Sam domain association: the interaction between the lipid phosphatase Ship2 and the EphA2 receptor. Biochemistry 47: 12721-8.
93. Mills SJ, Persson C, Cozier G, Thomas MP, et al. 2012. A synthetic polyphosphoinositide headgroup surrogate in complex with SHIP2 provides a rationale for drug discovery. ACS Chem Biol 7: 822-8.
94. Sali A, Blundell TL. 1993. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234: 779-815.
95. Soding J, Biegert A, Lupas AN. 2005. The HHpred interactive server for protein homology detection and structure prediction. Nucleic Acids Res 33: W244-8.
96. Poy F, Yaffe MB, Sayos J, Saxena K, et al. 1999. Crystal structures of the XLP protein SAP reveal a class of SH2 domains with extended, phosphotyrosine-independent sequence recognition. Mol Cell 4: 555-61.
97. Kavran JM, Klein DE, Lee A, Falasca M, et al. 1998. Specificity and promiscuity in phosphoinositide binding by pleckstrin homology domains. J Biol Chem 273: 30497-508.
98. Alessi DR, Deak M, Casamayor A, Caudwell FB, et al. 1997. 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol 7: 776-89.
99. Dowler S, Currie RA, Downes CP, Alessi DR. 1999. DAPP1: a dual adaptor for phosphotyrosine and 3-phosphoinositides. Biochem J 342: 7-12.
100. Tiwari S, Choi HP, Matsuzawa T, Pypaert M, et al. 2009. Targeting of the GTPase Irgm1 to the phagosomal membrane via PtdIns(3, 4)P(2) and PtdIns(3, 4, 5)P(3) promotes immunity to mycobacteria. Nat Immunol 10: 907-17.
101. Hilpela P, Oberbanscheidt P, Hahne P, Hund M, et al. 2003. SWAP-70 identifies a transitional subset of actin filaments in motile cells. Mol Biol Cell 14: 3242-53.
102. Muraille E, Bruhns P, Pesesse X, Daeron M, et al. 2000. The SH2 domain containing inositol 5-phosphatase SHIP2 associates to the immunoreceptor tyrosine-based inhibition motif of Fc gammaRIIB in B cells under negative signaling. Immunol Lett 72: 7-15.
103. Pengal RA, Ganesan LP, Fang H, Marsh CB, et al. 2003. SHIP-2 inositol phosphatase is inducibly expressed in human monocytes and serves to regulate Fcgamma receptor-mediated signaling. J Biol Chem 278: 22657-63.
104. Koch A, Mancini A, El Bounkari O, Tamura T. 2005. The SH2-domian-containing inositol 5-phosphatase (SHIP)-2 binds to c-Met directly via tyrosine residue 1356 and involves hepatocyte growth factor (HGF)-induced lamellipodium formation, cell scattering and cell spreading. Oncogene 24: 3436-47.
105. Zhuang G, Hunter S, Hwang Y, Chen J. 2007. Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-Kinase-dependent Rac1 activation. J Biol Chem 282: 2683-94.
106. Lemeer S, Bluwstein A, Wu Z, Leberfinger J, et al. 2012. Phosphotyrosine mediated protein interactions of the discoidin domain receptor 1. J Proteomics 75: 3465-77.
107. Habib T, Hejna JA, Moses RE, Decker SJ. 1998. Growth factors and insulin stimulate tyrosine phosphorylation of the 51C/SHIP2 protein. J Biol Chem 273: 18605-9.
108. Cunningham DL, Sweet SM, Cooper HJ, Heath JK. 2010. Differential phosphoproteomics of fibroblast growth factor signaling: identification of Src family kinase-mediated phosphorylation events. J Proteome Res 9: 2317-28.
109. Xie J, Onnockx S, Vandenbroere I, Degraef C, et al. 2008. The docking properties of SHIP2 influence both JIP1 tyrosine phosphorylation and JNK activity. Cell Signal 20: 1432-41.
110. Hyvonen ME, Saurus P, Wasik A, Heikkila E, et al. 2010. Lipid phosphatase SHIP2 downregulates insulin signalling in podocytes. Mol Cell Endocrinol 328: 70-9.
111. Hasegawa J, Tokuda E, Tenno T, Tsujita K, et al. 2011. SH3YL1 regulates dorsal ruffle formation by a novel phosphoinositide-binding domain. J Cell Biol 193: 901-16.
112. Raaijmakers JH, Deneubourg L, Rehmann H, de Koning J, et al. 2007. The PI3K effector Arap3 interacts with the PI(3, 4, 5)P3 phosphatase SHIP2 in a SAM domain-dependent manner. Cell Signal 19: 1249-57.
113. Havrylov S, Rzhepetskyy Y, Malinowska A, Drobot L, et al. 2009. Proteins recruited by SH3 domains of Ruk/CIN85 adaptor identified by LC-MS/MS. Proteome Sci 7: 21.
114. Mertins P, Eberl HC, Renkawitz J, Olsen JV, et al. 2008. Investigation of protein-tyrosine phosphatase 1B function by quantitative proteomics. Mol Cell Proteomics 7: 1763-7.
115. Zwaenepoel K, Goris J, Erneux C, Parker PJ, et al. 2010. Protein phosphatase 2A PR130/B″alpha1 subunit binds to the SH2 domain-containing inositol polyphosphate 5-phosphatase 2 and prevents epidermal growth factor (EGF)-induced EGF receptor degradation sustaining EGF-mediated signaling. FASEB J 24: 538-47.
116. Giuriato S, Pesesse X, Bodin S, Sasaki T, et al. 2003. SH2-containing inositol 5-phosphatases 1 and 2 in blood platelets: their interactions and roles in the control of phosphatidylinositol 3, 4, 5-trisphosphate levels. Biochem J 376: 199-207.